Christopher Ray  Aker net worth and biography

Christopher Aker Biography and Net Worth

Mr. Aker joined Regulus in February 2011 and currently serves as Senior Vice President and General Counsel. Prior to joining Regulus, Mr. Aker served as the Senior Director, Administration and Senior Corporate Counsel for Phenomix Corporation, a privately-held biopharmaceutical company, and was responsible for operational and legal oversight. Prior to Phenomix, Mr. Aker was Senior Corporate Counsel at SUGEN, Inc., a wholly-owned subsidiary of Pharmacia, until its acquisition by Pfizer. Prior to SUGEN, Mr. Aker was in private practice with various law firms. Mr. Aker received his Bachelor of Arts degree in International Relations from the University of California, Davis and his J.D. from the Santa Clara University.

What is Christopher Ray Aker's net worth?

The estimated net worth of Christopher Ray Aker is at least $95,199.12 as of May 17th, 2021. Mr. Aker owns 41,754 shares of Regulus Therapeutics stock worth more than $95,199 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Aker may own. Additionally, Mr. Aker receives an annual salary of $524,790.00 as VP at Regulus Therapeutics. Learn More about Christopher Ray Aker's net worth.

How old is Christopher Ray Aker?

Mr. Aker is currently 63 years old. There are 4 older executives and no younger executives at Regulus Therapeutics. Learn More on Christopher Ray Aker's age.

What is Christopher Ray Aker's salary?

As the VP of Regulus Therapeutics Inc., Mr. Aker earns $524,790.00 per year. The highest earning executive at Regulus Therapeutics is Mr. Joseph P. Hagan M.B.A., CEO & Director, who commands a salary of $920,730.00 per year. Learn More on Christopher Ray Aker's salary.

How do I contact Christopher Ray Aker?

The corporate mailing address for Mr. Aker and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Christopher Ray Aker's contact information.

Has Christopher Ray Aker been buying or selling shares of Regulus Therapeutics?

Christopher Ray Aker has not been actively trading shares of Regulus Therapeutics during the last quarter. Most recently, Christopher Ray Aker sold 860 shares of the business's stock in a transaction on Monday, May 17th. The shares were sold at an average price of $0.89, for a transaction totalling $765.40. Following the completion of the sale, the vice president now directly owns 41,754 shares of the company's stock, valued at $37,161.06. Learn More on Christopher Ray Aker's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), Denis Drygin (Insider), and Joseph Hagan (CEO). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 20,048 shares worth more than $23,857.12. The most recent insider tranaction occured on January, 18th when CFO Crispina Calsada sold 5,468 shares worth more than $6,506.92. Insiders at Regulus Therapeutics own 8.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 1/18/2024.

Christopher Ray Aker Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2021Sell860$0.89$765.4041,754View SEC Filing Icon  
2/16/2021Sell828$1.72$1,424.1642,614View SEC Filing Icon  
8/14/2020Sell872$0.61$531.9226,638View SEC Filing Icon  
5/15/2020Sell909$0.63$572.6727,510View SEC Filing Icon  
2/18/2020Sell888$0.83$737.0428,419View SEC Filing Icon  
1/2/2020Sell2,239$0.97$2,171.8329,307View SEC Filing Icon  
11/14/2019Sell833$0.64$533.1231,546View SEC Filing Icon  
10/1/2019Sell2,346$0.68$1,595.2832,379View SEC Filing Icon  
8/15/2019Sell899$0.55$494.45View SEC Filing Icon  
7/1/2019Sell2,225$1.31$2,914.7535,624View SEC Filing Icon  
5/15/2019Sell6,950$1.41$9,799.5066,259View SEC Filing Icon  
4/1/2019Sell2,710$0.98$2,655.806,287View SEC Filing Icon  
See Full Table

Christopher Ray Aker Buying and Selling Activity at Regulus Therapeutics

This chart shows Christopher Ray Aker's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.28
Low: $2.13
High: $2.34

50 Day Range

MA: $2.14
Low: $1.38
High: $2.88

2 Week Range

Now: $2.28
Low: $1.08
High: $3.79

Volume

62,853 shs

Average Volume

2,482,254 shs

Market Capitalization

$149.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56